Research To Practice | Oncology Videos Research To Practice
-
- Science
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.
-
- video
Non-Small Cell Cancer | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Non-Small Cell Lung Cancer with an EGFR Mutation
Featuring perspectives from Ms Marianne J Davies, Dr Alexander I Spira, Ms Jillian Thompson and Dr Helena Yu, including the following topics:
Introduction (0:00) The Importance of EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) (7:02) The Role of Osimertinib in Managing Localized and Locally Advanced NSCLC with an EGFR Mutation (11:58) Established First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (32:38) Newly Approved and Promising Investigational Approaches to First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (37:45) Common Toxicities Associated with Amivantamab (45:07) The Current and Future Management of Progressive NSCLC with an EGFR Mutation (55:06) Tolerability and Other Practical Considerations with HER3-DXd (1:01:06) Treatment for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations (1:18:26) CME information and select publications -
- video
Metastatic Triple-Negative Breast Cancer | Virtual Case Library: Metastatic Triple-Negative Breast Cancer
Featuring perspectives from Dr Julia Foldi, Dr Laura Huppert, Dr Rita Nanda, Dr Saba Shaikh and Dr Sara M Tolaney, including the following topics:
Introduction: Overview of metastatic triple-negative breast cancer (mTNBC)
Current and emerging strategies for patients with mTNBC (0:00) First-line treatment of mTNBC — Chemotherapy with or without immunotherapy
Case: A woman in her early 60s with a history of well-controlled HIV is diagnosed with mTNBC — Dr Shaikh (6:10) Case: A woman in her mid 40s with de novo mTNBC — Dr Huppert (20:41) Case: A woman in her late 50s with mTNBC receives up-front pembrolizumab/chemotherapy — Dr Foldi (42:15) Antibody-drug conjugates (ADCs) in the management of mTNBC
ADCs in the management of mTNBC; sequencing of these agents and ongoing investigations (51:45) Case: A woman in her early 50s with mTNBC receives first-line chemotherapy/immune checkpoint inhibitor followed by sacituzumab govitecan — Dr Shaikh (1:05:32) Case: A woman in her late 30s with mTNBC receives sacituzumab govitecan — Dr Huppert (1:14:21) Case: A woman in her early 40s with mTNBC (IHC 1+) with sacituzumab govitecan-intolerant disease experiences an excellent response to trastuzumab deruxtecan (T-DXd) — Dr Foldi (1:27:30) Case: A woman in her mid 50s with HER2-low metastatic breast cancer receives T-DXd — Dr Shaikh (1:42:00) PARP inhibition for the treatment of mTNBC
Efficacy and tolerability of olaparib in patients with a germline BRCA mutation and HER2-negative breast cancer (1:49:49) Case: A woman in her mid 30s with mTNBC receives olaparib — Dr Foldi (1:54:28) Case: A woman in her mid 60s with mTNBC and a BRCA mutation receives olaparib — Dr Huppert (1:59:11) Case: A woman in her mid 40s with a BRCA1 germline mutation and mTNBC receives olaparib — Dr Shaikh (2:03:45) CME information and select publications
-
- video
Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition
Featuring perspectives from Dr Matthew D Galsky, including the following topics:
HER2 alterations in urothelial cancer and current targeting approaches (0:00) Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39) Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31) Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57) Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25) Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34) Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48) CME information and select publications -
- video
Gastroesophageal Cancer | Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Dr Sunnie Kim, including the following topics:
Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer — Dr Kim (0:00) Case: A man in his mid 50s with poorly differentiated mismatch repair-deficient advanced gastric cancer receives first-line nivolumab/ipilimumab (49:22) Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who experienced disease progression on FOLFOX/trastuzumab receives trastuzumab deruxtecan (54:48) Case: A man in his mid 60s with Stage IV, PD-L1-positive GEJ adenocarcinoma (58:11) Case: A man in his early 40s with metastatic CLDN18.2-positive gastric/GEJ adenocarcinoma receives zolbetuximab (1:01:10) CME information and select publications -
- video
Gastroesophageal Cancer | Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer
Featuring perspectives from Prof Eric Van Cutsem, including the following topics:
Immune Checkpoint Inhibitors in Localized Gastroesophageal (GE) Cancers
Introduction (0:00) Case: A man in his mid 50s with localized, poorly differentiated signet ring, mismatch repair-deficient advanced gastric adenocarcinoma — Sunnie Kim, MD (3:39) HER2-Positive GE Cancers
Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma and disease progression on FOLFOX/trastuzumab (PD-L1 CPS 0) — Dr Kim (19:22) First-Line Treatment of Metastatic Gastric and GEJ Adenocarcinoma
Case: A man in his early 40s who presents with metastatic GEJ adenocarcinoma (CLDN18.2-positive, PD-L1 CPS 2) in visceral crisis from lung metastases — Dr Kim (38:53) Case: A man in his mid 60s with metastatic GEJ adenocarcinoma (PD-L1 CPS 20) — Dr Kim (50:50) CME information and select publications -
- video
Myelofibrosis | Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series
Featuring perspectives from Dr Ruben A Mesa, including the following topics:
Introduction: Journal Club with Dr Mesa (0:00) Case: A woman in her mid 80s with an interesting and unusual presentation of primary myelofibrosis — Bhavana (Tina) Bhatnagar, DO (25:33) Case: A man in his early 70s, asymptomatic, with lower-risk primary MF (JAK2 V617F mutation) — Susannah Friemel, MD (29:42) Case: A woman in her early 80s with pancytopenia and palpable spleen who is diagnosed with primary MF — Jeanne Palmer, MD (35:08) Case: A man in his early 70s with multiple comorbidities and MF (CALR mutation) who receives ruxolitinib 10 mg BID — Ranju Gupta, MD (42:40) ASH 2023 Review (46:13) Faculty Survey (55:41) CME information and select publications